Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2010

View Archived Issues

PHY-906 beneficial when added to capecitabine in phase II pancreatic cancer trial

Perifosine plus capecitabine active in mCRC; phase III study planned

Enrollment begins into clinical trial of Alinia for acute uncomplicated influenza

PharmAthene submits White Paper for development of SparVax anthrax vaccine

Kyowa Hakko Kirin and Hisamitsu sign distribution agreement in Japan for KW-2246

Abbott and Pierre Fabre sign exclusive worldwide licensing agreement for h224G11

MK-0646 added to gemcitabine and erlotinib active in advanced pancreatic cancer

GI-4000 plus gemcitabine evaluated in ras mutation-bearing pancreas cancer

Mitaplatin targets both mitochondria and nucleus selectively in cancer cells

YM BioSciences merges with Cytopia

NeuroMed describes novel T-type voltage-gated calcium channel blockers

Novel antimicrobial agents discovered by French scientists

Kalbitor now available on U.S. market

Anadys discovers NS5B inhibitors for treatment of HCV infections

Novel NURR1/NOT ligands described by sanofi-aventis

Ariad claims new activin receptor-like kinase inhibitors for cancer therapy

FDA accepts Topica's luliconazole IND to begin trials in onychomycosis

Pearl raises funds to advance PT-003 combination bronchodilator for COPD

Pervasis receives FDA clearance for pivotal phase III Vascugel trial

Mepact for osteosarcoma reaches first market

Edoxaban enters phase III thromboembolism trial

FDA reports safety risk associated with HIV drug Videx

Cephalon enters agreement to acquire Mepha

Neuralstem treats first patient in ALS stem cell trial

Novartis reports fourth quarter and full year 2009 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.